157 related articles for article (PubMed ID: 10880728)
21. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen CY; Zhou Y; Cui YM; Yang T; Zhao X; Wu Y
J Clin Pharm Ther; 2019 Apr; 44(2):300-311. PubMed ID: 30636182
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL
Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415
[TBL] [Abstract][Full Text] [Related]
23. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
Ortenzi A; Paggi A; Foschi N; Sabbatini D; Pistoli E
Funct Neurol; 2008; 23(2):97-100. PubMed ID: 18671911
[TBL] [Abstract][Full Text] [Related]
24. Relation of blood platelet count during carbamazepine and oxcarbazepine treatment with daily dose, and serum concentrations of carbamazepine, carbamazepine-10, 11-epoxide, and 10-hydroxycarbazepine.
Tutor-Crespo MJ; Hermida J; Tutor JC
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):91-4. PubMed ID: 17690747
[TBL] [Abstract][Full Text] [Related]
25. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.
Striano S; Striano P; Di Nocera P; Italiano D; Fasiello C; Ruosi P; Bilo L; Pisani F
Epilepsy Res; 2006 May; 69(2):170-6. PubMed ID: 16515857
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
Viola MS; Bercellini MA; Saidón P; Rubio MC
Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
[TBL] [Abstract][Full Text] [Related]
27. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy.
Barcs G; Walker EB; Elger CE; Scaramelli A; Stefan H; Sturm Y; Moore A; Flesch G; Kramer L; D'Souza J
Epilepsia; 2000 Dec; 41(12):1597-607. PubMed ID: 11114219
[TBL] [Abstract][Full Text] [Related]
28. 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs.
Armijo JA; Vega-Gil N; Shushtarian M; Adín J; Herranz JL
Ther Drug Monit; 2005 Apr; 27(2):199-204. PubMed ID: 15795652
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Peng J; Zhang HN; Liu ZS; Xu H; Wang Y
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):684-92. PubMed ID: 24887335
[TBL] [Abstract][Full Text] [Related]
30. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.
Lin CH; Lu CH; Wang FJ; Tsai MH; Chang WN; Tsai NW; Lai SL; Tseng YL; Chuang YC
Clin Neuropharmacol; 2010; 33(6):293-6. PubMed ID: 20881597
[TBL] [Abstract][Full Text] [Related]
31. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.
Rosaria Muscatello M; Pacetti M; Cacciola M; La Torre D; Zoccali R; D'Arrigo C; Migliardi G; Spina E
Epilepsia; 2005 May; 46(5):771-4. PubMed ID: 15857446
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
33. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine.
Marchi N; Guiso G; Rizzi M; Pirker S; Novak K; Czech T; Baumgartner C; Janigro D; Caccia S; Vezzani A
Epilepsia; 2005 Oct; 46(10):1613-9. PubMed ID: 16190932
[TBL] [Abstract][Full Text] [Related]
34. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid.
Tartara A; Galimberti CA; Manni R; Morini R; Limido G; Gatti G; Bartoli A; Strada G; Perucca E
Br J Clin Pharmacol; 1993 Oct; 36(4):366-8. PubMed ID: 12959317
[TBL] [Abstract][Full Text] [Related]
35. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
Pisani F; Fazio A; Oteri G; Artesi C; Xiao B; Perucca E; Di Perri R
Acta Neurol Scand; 1994 Aug; 90(2):130-2. PubMed ID: 7801739
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.
Chen X; Gu E; Wang S; Zheng X; Chen M; Wang L; Hu G; Cai JP; Zhou H
J Chromatogr Sci; 2016 Mar; 54(3):334-42. PubMed ID: 26499119
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Flesch G; Czendlik C; Renard D; Lloyd P
Drug Metab Dispos; 2011 Jun; 39(6):1103-10. PubMed ID: 21389120
[TBL] [Abstract][Full Text] [Related]
38. Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy.
Shen C; Zhang B; Liu Z; Tang Y; Zhang Y; Wang S; Guo Y; Ding Y; Wang S; Ding M
Seizure; 2017 Oct; 51():102-106. PubMed ID: 28837897
[TBL] [Abstract][Full Text] [Related]
39. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.
Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Jan; 54(1):108-16. PubMed ID: 22812691
[TBL] [Abstract][Full Text] [Related]
40. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
